Neurology — Movement Disorders

Tavapadon: TEMPO Phase 3 Trials

First-in-Class Selective D1/D5 Dopamine Partial Agonist for Parkinson's Disease — Supreme Neurologist Level

Phase 3 RCT n=1,340 (TEMPO-1/2/3) JAMA Neurology 2026 NDA Submitted FDA 2025
TEMPO Program — Primary Endpoints Summary

Efficacy + Unprecedented ICD Safety Profile

−9.1 pts
MDS-UPDRS II+III (TEMPO-2)
vs placebo −1.2 pts | P < .001
+1.10 hr
Good ON-Time (TEMPO-3)
vs placebo | P < .001
1.2%
ICD Incidence (All TEMPO)
vs D2/D3 agonists: 17–28%
~1%
Sleep Attacks (NS vs placebo)
vs D2/D3: 1–9%
Pharmacology — Receptor Binding Profile

D1/D5 Selective: Ki Values and Intrinsic Activity

Receptor Ki (nM) Functional Activity EC50 (nM)
D1 9 Partial agonist (65% intrinsic) 19
D5 13 Partial agonist (81% intrinsic) 17
D2 >6,720 Negligible
D3 5,240 Negligible
D4 4,870 Negligible

Selectivity: D1 vs D2 >700-fold | D1 vs D3 >580-fold | D5 vs D3 >400-fold

Pharmacokinetics

24-Hour Half-Life Supports Once-Daily Dosing

~24 hr
Half-life (t½)
1–3 hr
Tmax
CYP3A4
Metabolism
5–15 mg
Dose Range
QD
Frequency
None
Food Effect
Mechanism — Basal Ganglia Motor Circuit

D1 vs D2 Pathway: Motor Circuit Dysfunction in PD

Direct Pathway (D1) — "GO" Signal
SNc Dopamine
D1 MSNs (Striatum)
GPi/SNr
Thalamus
Cortex → Movement

In PD: Dopamine loss → ↓D1 activation → ↓direct pathway → ↑GPi output → Thalamic suppression → Bradykinesia

Indirect Pathway (D2) — "STOP" Signal
SNc Dopamine
D2 MSNs (Striatum)
GPe
STN
GPi
Thalamus

In PD: Dopamine loss → ↓D2 activation → ↑indirect pathway → ↑GPi output → Thalamic suppression → Bradykinesia

Critical Differentiator: ICD Mechanism
D2/D3 agonists (Pramipexole, Ropinirole): Stimulate D3 receptors in nucleus accumbens (VTA-NAc mesolimbic pathway) → Excessive reward signaling → ICD (pathological gambling, compulsive shopping, binge eating, hypersexuality) in 17–28% of patients.

Tavapadon: D1/D5 selective, negligible D3 affinity (Ki >5,000 nM) → No mesolimbic activation → ICD rate ~1% across all TEMPO trials.
TEMPO Clinical Development Program

Phase 3 Trials: Monotherapy + Adjunctive

TEMPO-1
Monotherapy, Fixed dose
n=529 | 27 weeks
MDS-UPDRS II+III: −9.7 to −10.2 pts ✓
ICD: 0%
TEMPO-2
Monotherapy, Flexible 5–15mg
n=304 | 27 weeks
MDS-UPDRS II+III: −9.1 pts ✓
ICD: 1.3%
TEMPO-3
Adjunctive to Levodopa
n=507 | 27 weeks
Good ON-time: +1.1 hr ✓
ICD: 1.2%
Safety — ICD Comparison

Tavapadon vs D2/D3 Agonists: Paradigm Shift in Safety

Adverse Event Tavapadon (TEMPO) D2/D3 Agonists (Historical)
Impulse Control Disorders 1.2–1.3% 17–28%
Sleep Attacks ~1% (NS vs placebo) 1–9%
Somnolence 1–3% 5–15%
Hallucinations 4–6% 5–10%
Dyskinesia 1–2% 2–5%
Nausea 10–18% 15–25%
Bottom Line
Comparable motor efficacy + 20× lower ICD rate + comparable motor efficacy = potential paradigm shift in dopamine agonist selection
Clinical Comparison

vs Current Adjunctive Therapies for Motor Fluctuations

Therapy Mechanism ON-time ICD Risk Dosing
Tavapadon D1/D5 partial agonist ↑↑ ~1% QD
Pramipexole D2/D3 full agonist 17–28% TID/QD
Ropinirole D2/D3 partial agonist 12–20% TID/QD
Opicapone (COMT-I) Extend levodopa Minimal QD
Amantadine (ER) NMDA antagonist Dyskinesia ↓ Minimal QD
Clinical Utility

Ideal Candidate Selection

✓ Tavapadon Preferred
• Treatment-naïve early PD
• ICD risk factors (history, family Hx)
• Sleep disorders on D2/D3 agonists
• Geriatric patients (start low)
• Cognitive vulnerability (MCI, >75y)
• Autonomic dysfunction (OH)
• Pill burden concerns
• Once-daily dosing preference
✗ Alternatives Preferred
• Primary dyskinesia (amantadine)
• Advanced PD (LCIG, apomorphine, DBS)
• Active ICD (avoid all agonists)
• Failed/inadequate tavapadon
• Specific formulary constraints
• Cost/access limitations
Take-Home Points for Practice